Literature DB >> 12658558

Ocular penetration of acyclovir and its peptide prodrugs valacyclovir and val-valacyclovir following systemic administration in rabbits: An evaluation using ocular microdialysis and LC-MS.

Clapton Dias1, Yasser Nashed, Harisha Atluri, Ashim Mitra.   

Abstract

PURPOSE: To investigate the ocular penetration of acyclovir and its prodrugs following systemic administration and to elucidate the mechanism of penetration.
METHODS: Hydrophilic peptide prodrugs of acyclovir were infused intravenously in New Zealand albino rabbits over 45 min at a dose equivalent to 30 mmoles/kg acyclovir. Aqueous and vitreous humor samples were obtained utilizing ocular microdialysis and blood samples were obtained from the mid ear vein using a cannula.
RESULTS: The plasma bioavailability for acyclovir, valacyclovir and val-valacyclovir were similar with area under curve values being 896.24 (+/-143.58), 776.54 (+/-197.52), 824.69 (+/-217.43) min x micromoles/L respectively. Anterior segment area under curve values were 53.70 (+/-35.58), 139.85 (+/-9.43) and 291.05 (+/-88.13) min x micromoles/L respectively while the mean residence time values were 46.47 (+/-24.94), 76.30 (+/-7.24) and 188.39 (+/-80.73) min respectively. Vitreous levels of the prodrugs were not measurable.
CONCLUSIONS: The valine and valine-valine ester prodrugs of ACV penetrated the anterior segment of the eye much better than acyclovir alone, probably via a carrier mediated transport mechanism.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12658558     DOI: 10.1076/ceyr.25.4.243.13488

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  13 in total

Review 1.  Ocular cytochrome P450s and transporters: roles in disease and endobiotic and xenobiotic disposition.

Authors:  Mariko Nakano; Catherine M Lockhart; Edward J Kelly; Allan E Rettie
Journal:  Drug Metab Rev       Date:  2014-05-26       Impact factor: 4.518

2.  Dipeptide prodrug approach to evade efflux pumps and CYP3A4 metabolism of lopinavir.

Authors:  Mitesh Patel; Ye Sheng; Nanda K Mandava; Dhananjay Pal; Ashim K Mitra
Journal:  Int J Pharm       Date:  2014-09-26       Impact factor: 5.875

3.  Ex vivo investigation of ocular tissue distribution following intravitreal administration of connexin43 mimetic peptide using the microdialysis technique and LC-MS/MS.

Authors:  Rohit Bisht; Abhirup Mandal; Ilva D Rupenthal; Ashim K Mitra
Journal:  Drug Deliv Transl Res       Date:  2016-12       Impact factor: 4.617

4.  NextGen Brain Microdialysis: Applying Modern Metabolomics Technology to the Analysis of Extracellular Fluid in the Central Nervous System.

Authors:  Chi-Ya Kao; Elmira Anderzhanova; John M Asara; Carsten T Wotjak; Christoph W Turck
Journal:  Mol Neuropsychiatry       Date:  2015-04-29

Review 5.  Update on the Management of Infectious Keratitis.

Authors:  Ariana Austin; Tom Lietman; Jennifer Rose-Nussbaumer
Journal:  Ophthalmology       Date:  2017-09-21       Impact factor: 12.079

Review 6.  Antimicrobial guide to posterior segment infections.

Authors:  Tapan P Patel; David N Zacks; Vaidehi S Dedania
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-11-06       Impact factor: 3.117

7.  Peptide prodrugs: improved oral absorption of lopinavir, a HIV protease inhibitor.

Authors:  Sheetal Agarwal; S H S Boddu; Ritesh Jain; Swapan Samanta; Dhananjay Pal; Ashim K Mitra
Journal:  Int J Pharm       Date:  2008-03-28       Impact factor: 5.875

8.  Synthesis, metabolism and cellular permeability of enzymatically stable dipeptide prodrugs of acyclovir.

Authors:  Ravi S Talluri; Swapan K Samanta; Ripal Gaudana; Ashim K Mitra
Journal:  Int J Pharm       Date:  2008-06-23       Impact factor: 5.875

Review 9.  Recent perspectives in ocular drug delivery.

Authors:  Ripal Gaudana; J Jwala; Sai H S Boddu; Ashim K Mitra
Journal:  Pharm Res       Date:  2008-08-29       Impact factor: 4.200

Review 10.  Ocular manifestations of herpes simplex virus.

Authors:  Gabriel S Valerio; Charles C Lin
Journal:  Curr Opin Ophthalmol       Date:  2019-11       Impact factor: 3.761

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.